[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unknown-primary-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unknown-primary-tumors":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,77,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100633240","study-of-high-precision-evaluation-of-molecular-residual-disease-through-a-platform-for-cancer-tracking-and-interception-sherlock-100633240",false,"NCT07524114","Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","SHERLOCK","Inclusion Criteria:\n\n1. Patients with histopathological confirmation of cancer. Patients whose diagnosis are made by cytology may also be considered for this study. For tumor types that are typically diagnosed using unequivocal imaging findings or biomarker profiles (e.g. hepatocellular cancer, uveal melanoma), they can be eligible without histopathological or cytological confirmation.\n2. Patients must have cancer that is planned for or has undergone curative intent treatment (e.g. surgery, definitive radiation, definitive chemoradiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiation, etc). Curative intent treatment must be completed within 12 months of study entry. For patients on adjuvant\u002Fmaintenance endocrine or biological therapy (e.g. bevacizumab, immunotherapy, etc), enrollment within 12 months of completion of curative intent treatment is allowed.\n3. Patient must be ≥ 18 years old.\n4. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1. History of another active invasive cancer within 2 years prior to study enrolment. Exceptions include squamous and basal cell carcinoma of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 2 years.\n2. Prior allogeneic stem cell transplant","ALL","18 Years",{"count":19,"type":20},7000,"ESTIMATED","OBSERVATIONAL","This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types. Results of ctDNA testing will be provided for clinical decisions and to determine eligibility for other linked interventional interception therapeutic studies, each of which will have a separate protocol.",[24,25,26,27,28,29,30,31,32,33],"Breast Cancer","Lung Cancer","Melanoma","Gynecologic Cancer","Genitourinary Cancer","Pancreatobiliary Cancer","Gastrointestinal Cancer","Head and Neck Cancer","Rare Cancer","Unknown Primary Tumors",[35,36,37],"Minimal Residual Disease","Liquid Biopsy","Circulating Tumor DNA","RECRUITING","2026-05-06",{"date":41,"type":42},"2026-05-11","ACTUAL",{"date":44,"type":42},"2026-03-31",{"date":46,"type":20},"2031-03-31",{"name":48,"class":49},"University Health Network, Toronto","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100526918","pacific-cup-classifies-cancer-of-unknown-primary-100526918","NCT06140992","PaCIFiC-CUP Classifies Cancer of Unknown Primary","PaCIFiC-CUP：Pan-Cancer Integrated Fingerprinting Classifier for Identifying the Origin of Cancer of Unknown Primary: A Multi-Center Prospective Cohort Study","Inclusion Criteria:\n\n1. The patient specimens were obtained from the Sun Yat-sen University Cancer Center and affiliated cooperating centers, with written consent from the patients authorizing the use of the specimens for research purposes.\n2. Following standard assessments (medical history, physical examination, complete blood count, biochemistry, computed tomography scans of the neck, chest, abdomen, and pelvis, targeted evaluations of all symptomatic areas, pathology, and immunohistochemistry), the diagnosis was determined as a primary site unknown tumor (including adenocarcinoma, squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, sarcoma, etc).\n3. The diagnosis was confirmed at the participating institution and the patient had received systemic therapy.\n4. Complete clinical, pathological, and follow-up data for the patients can be obtained.\n5. ECOG performance status score: 0-2 points.\n\nExclusion Criteria:\n\n1. Pregnant or lactating female patients.\n2. Tumor tissue sample size is too small (tumor tissue accounts for \\\u003C70% in the biopsy or slice tissue).\n3. Organ transplant or history of non-autologous (allogeneic) bone marrow or stem cell transplantation.\n4. History of previous tumors, with the current condition being a recurrent tumor.\n5. Hematological malignancies (excluding lymphoma).\n6. Other diseases that may severely impact patient survival, such as severe cardiovascular or cerebrovascular diseases, sepsis, severe trauma or burns, etc.","80 Years",{"count":60,"type":20},120,"This study aims to initially utilize machine learning on pan-cancer DNA methylation data from public databases to construct a DNA methylation classification model (PaCIFiC-CUP, pan-cancer integrated fingerprinting classifier of CUP) for diagnosing various types of cancer, particularly the primary site of cancer of unknown primary. The goal is to achieve diagnosis of cancer pathology type by analyzing the DNA methylation patterns of cancer specimens, thereby guiding subsequent precision treatment for cancer.",[33,63],"DNA Methylation",[33,65,66,67],"DNA methylation","Large Language Model","Pan-cancer","2026-04-22",{"date":70,"type":42},"2026-04-23",{"date":72,"type":42},"2023-07-01",{"date":74,"type":20},"2026-12-31",{"name":76,"class":49},"Sun Yat-sen University",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100383469","phase-2-investigating-the-effects-of-atezolizumab-in-people-whose-tumour-dna-or-rna-indicates-possible-sensitivity-100383469","NCT04273061","Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention","CAPTIV-8","Inclusion Criteria:\n\n* Age greater than or equal to 18 years at the time of signature of informed consent.\n* Participants with an incurable solid tumour who have undergone whole genome and transcriptome analysis (WGTA) as part of Personalized OncoGenomics (POG) or equivalent program.\n\n  a. Participants must have had successful sequencing of their tumour, been formally reviewed by the POG (or POG-approved) genome analysts and found to have CAPTIV-8 factors identified (including Immune, Burden, Variant (IBV) score ≥ 5), been reviewed at the Molecular Tumour Board (MTB) (or site equivalent), and allocated to a specific tumour-defined cohort (that is open for enrolment) with a final opinion documented.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Participants must have measurable disease, as defined by RECIST 1.1.\n* Life expectancy of at least 12 weeks.\n* Adequate hematologic and end-organ function, as defined by the following laboratory results obtained within 28 days prior to the first study treatment:\n\n  1. Absolute neutrophil count (ANC) ≥ 1500 cells\u002FµL without granulocyte colony- stimulating factor support.\n  2. White blood cell (WBC) counts \\> 2500\u002FµL.\n  3. Lymphocyte count ≥ 500\u002FµL.\n  4. Serum albumin ≥ 2.5 g\u002FdL.\n  5. Platelet count ≥ 100,000\u002FµL without transfusion (without transfusion within 2 weeks of laboratory test used to determine eligibility).\n  6. Hemoglobin ≥ 9.0 g\u002FdL, participants may be transfused or receive erythropoietic treatment to meet this criterion.\n  7. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤ 1.5 × Upper Limit of Normal (ULN). This applies only to participants who are not receiving therapeutic anticoagulation; participants receiving therapeutic anticoagulation must have an INR or aPTT within therapeutic limits for at least 1 week prior to enrolment.\n  8. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × ULN with the following exceptions: i) Participants with documented liver metastases: AST and\u002For ALT ≤ 5 × ULN. ii) Participants with documented liver or bone metastases: ALP ≤ 5 × ULN.\n  9. Serum bilirubin ≤ 1.5 × ULN. Participants with known Gilbert's syndrome who have serum bilirubin level ≤ 3 × ULN may be enrolled.\n  10. Serum creatinine ≤ 1.5 × ULN.\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than 1% (one percent) per year during the treatment period and for at least 5 months after the last dose of atezolizumab.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse with a female partner of childbearing potential or who is pregnant) or use contraceptive measures that result in a failure rate of less than 1% (one percent) per year, and agreement to refrain from donating sperm, during the treatment period and for at least 5 months after the last dose of atezolizumab.\n* Asymptomatic participants with treated or untreated CNS lesions are eligible provided that all of the following criteria are met:\n\n  1. Measurable disease, per RECIST 1.1, must be present.\n  2. The participant has no history of intracranial hemorrhage or spinal cord hemorrhage.\n  3. The participant has not undergone stereotactic radiotherapy within 7 days prior to the initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, or neurosurgical resection within 28 days prior to initiation of study treatment.\n  4. The participant has no ongoing requirement for corticosteroids as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted.\n* Ability to give informed consent for the study procedures defined in this protocol.\n\nExclusion Criteria:\n\n* Any prior treatment with monoclonal antibodies targeting the Programmed Death 1\u002FLigand (PD-1\u002FPD-L1) axis, including antibody-drug conjugates and other experimental agents.\n* Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days or five half-lives of the drug, whichever is longer, prior to enrollment. Participants receiving gonadotropin releasing hormone (GnRH) analogues may continue to receive treatment while participating in CAPTIV-8.\n* Pregnancy or breastfeeding.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.\n* Active autoimmune disease at any point within the last 2 years prior to enrollment including but not limited to:\n\n  1. Myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n  2. Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone may be eligible for this study.\n  3. Participants with controlled Type I diabetes mellitus on a stable dose of insulin regimen are eligible for this study.\n* Participants with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., participants with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\n\n  1. Rash must cover less than 10% (ten percent) of body surface area (BSA).\n  2. Disease is well controlled at baseline and only requiring low potency topical steroids.\n  3. No acute exacerbations of underlying condition within the last 12 months requiring treatment with either psoralen plus ultraviolet radiation (PUVA), methotrexate, retinoids, biologic agents, oral calcineurin inhibitors or high potency or oral steroids.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Positive test for HIV (participants with a history of\u002For symptoms of HIV are eligible only if serological tests are negative).\n* Participants with hepatitis B virus (HBV) are excluded if one of the following conditions is met:\n\n  1. Positive hepatitis B surface antigen (HBsAg) test at screening; or\n  2. Negative or positive hepatitis B surface antibody (HBsAb) test at screening accompanied by a positive total hepatitis B core antibody (HBcAb) test followed by a positive (per local laboratory definition) HBV DNA test.\n* Positive hepatitis C virus (HCV) antibody test followed by a positive HCV RNA test at screening.\n* Active tuberculosis.\n* Severe infections within 2 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina.\n* Major surgical procedure within 21 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study.\n* Prior allogeneic stem cell or solid organ transplant.\n* Treatment with systemic immunostimulatory agents (including but not limited to interferons, interleukin-2 (IL-2)) within 6 weeks or five half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1.\n* Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumour necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic immunosuppressive medications during the trial.\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab.\n* Participants who are otherwise felt by the treating clinician to be unfit to proceed with this protocol.",{"count":86,"type":20},200,"INTERVENTIONAL",[89],"PHASE2","This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer.\n\nThis is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.",[24,25,30,28,27,92,33,31,93],"Sarcoma","Skin Cancer",[95,96,97,98,99,100,101,102],"Genomic analysis","Atezolizumab","Whole genome and transcriptome analysis","Immune Burden Variant score","Immune checkpoint inhibition","Personalized OncoGenomics","Phase 2","Precision targeting","2025-09-17",{"date":105,"type":42},"2025-09-22",{"date":107,"type":42},"2020-06-17",{"date":109,"type":20},"2027-10",{"name":111,"class":49},"British Columbia Cancer Agency",2,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":50},"100442827","solving-riddles-through-sequencing-100442827","NCT05046444","Solving Riddles Through Sequencing","Testing the Diagnostic Supremacy of Sequencing-only Approaches in Hematologic Malignancies: an Observational Trial","SIRIUS","Inclusion Criteria:\n\n* Patients having been investigated with a suspected hematological disorder and:\n* Having unclear diagnosis after internal routine diagnosis\n* Unusual clinical course\n* Unusual r\u002Fr status or non-responder\n* Multiple parallel hematological conditions\n* Difficult\u002Frare therapy associated\u002Fsecondary neoplasms\n* Current diagnostic workup is not satisfactory in terms of (1) accuracy (2) clinical behavior\n* Only samples of patients min. 18 years of age will be used\n* Material with a minimum of 20% tumor content in bone marrow or peripheral blood sample\n* Patient´s informed consent\n\nExclusion Criteria:\n\n* Sample is not fit for state-of-the-art diagnosis, fails initial quality control. For quality insurance we will exclude samples with wrong anticoagulant sent. Samples with damage due to meteorological reasons (freeze-thaw damage or elevated temperature) will be excluded.\n* Samples with to scarce material jeopardizing routine gold-standard diagnosis will be excluded (tumor content \\\u003C 20 %).","99 Years",{"count":123,"type":20},100,"During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients. This continuous evolution proceeded in parallel to seminal discoveries in basic science such as FISH, PCR and NGS. So far, the current WHO classification serves as reference to diagnostic decision making and is largely based on 5 diagnostic pillars: cytomorphology of peripheral blood and\u002For bone marrow smears, histology and immunohistochemistry of bone marrow trephine biopsies or lymph nodes, immunophenotyping, chromosome banding analysis supplemented by FISH analysis, molecular genetics including PCR and targeted panel sequencing via NGS. This leads to a swift diagnosis in 90 % of all cases. The leftover 10 % remain a challenge for hematopathologists and clinicians alike and are resolved through interdisciplinary teams in the context of specialized boards. With the advent of high throughput sequencing (mainly WGS and WTS) the possibility of a comprehensive and detailed portrait of the genetic alterations - specifically in challenging cases - has become a realistic alternative to classical methods. In SIRIUS the investigators will prospectively challenge this hypothesis to address the question of how often a better or final diagnosis can be delivered by WGS and\u002For WTS and if unclear cases can be efficiently resolved.",[126,127,128,129,130,33],"Leukemia","Hematologic Malignancy","Rare Diseases","Refractory Leukemia","Refractory Lymphoma","2024-12-14",{"date":133,"type":42},"2024-12-17",{"date":135,"type":42},"2022-01-19",{"date":137,"type":20},"2026-10-01",{"name":139,"class":140},"Munich Leukemia Laboratory","INDUSTRY"]